Suven Life Sciences Limited (SUVEN) — Announcement | 22 June 2026

· NSE Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings

Suven Life Sciences announced its participation in the BIO International Convention 2026 in San Diego from June 22-25, where it will showcase its CNS clinical pipeline including Ropanicant, Masupirdine, Samelisant, Usmarapride, and SUVN-I6107 to potential partners through 62 scheduled meetings. The company highlighted positive Phase 2b topline results for Ropanicant in major depressive disorder and outlined upcoming Phase 3 milestones.

📄 View Original Announcement (PDF)

About Suven Life Sciences Limited (SUVEN)

Healthcare · Healthcare · Listed on NSE

Market Cap: ₹10,762.81 Cr ROE: -80.9% ROCE: -80.7%

View full SUVEN stock details →

📡 Get AI alerts when SUVEN files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track SUVEN — Free

📊 More SUVEN filings

See all SUVEN filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when SUVEN files new disclosures

Track SUVEN filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track SUVEN — Free

Free account · 2 AI queries/day